المؤلفون: S. E. Titov, S. A. Lukyanov, S. V. Sergiyko, Yu. A. Veryaskina, T. E. Ilyina, E. S. Kozorezov, S. L. Vorobyov, С. Е. Титов, С. А. Лукьянов, С. В. Сергийко, Ю. А. Веряскина, Т. Е. Ильина, Е. С. Козорезова, С. Л. Воробьев

المساهمون: The research was carried out within the framework of the state task (Unified State information system for accounting of research, development and technological works for civil purposes, No. 121040100268-9) and at the expense of a grant from the Russian Science Foundation (grant No. 20-14-00074-P)., Исследование выполнено в рамках государственного задания (Единая государственная информационная система учета научно-исследовательских, опытно-конструкторских и технологических работ гражданского назначения, № 121040100268-9) и за счет гранта Российского научного фонда (грант № 20-14-00074-П)

المصدر: Head and Neck Tumors (HNT); Том 13, № 3 (2023); 10-23 ; Опухоли головы и шеи; Том 13, № 3 (2023); 10-23 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-3

مصطلحات موضوعية: фолликулярная аденома щитовидной железы, микроРНК, молекулярная диагностика, массовое параллельное секвенирование, follicular thyroid adenoma, microRNA, molecular diagnostics, mass parallel sequencing

وصف الملف: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/910/591; Bongiovanni M., Spitale A., Faquin W.C. et al. The Bethesda System for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 2012;56(4):333–9. DOI:10.1159/000339959; Cibas E.S., Ali S.Z. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid 2017;27(11):1341–6. DOI:10.1089/thy.2017.0500; Schneider D.F., Cherney Stafford L.M., Brys N. et al. Gauging the extent of thyroidectomy for indeterminate thyroid nodules: an oncologic perspective. Endocr Pract 2017;23(4):442–50. DOI:10.4158/EP161540.OR; Stewardson P., Eszlinger M., Paschke R. Diagnosis of endocrine disease: usefulness of genetic testing of fine-needle aspirations for diagnosis of thyroid cancer. Eur J Endocrinol 2022;187(3):R41–52. DOI:10.1530/EJE-21-1293; Patel K.N., Yip L., Lubitz C.C. et al. The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg 2020;271(3):e21–93. DOI:10.1097/SLA.0000000000003580; Silaghi C.A., Lozovanu V., Georgescu C.E. et al. Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021;12:649522. DOI:10.3389/fendo.2021.649522; Wang M.M., Beckett K., Douek M. et al. Diagnostic value of molecular testing in sonographically suspicious thyroid nodules. J Endocr Soc 2020;4(9):bvaa081. DOI:10.1210/jendso/bvaa081; Azizi G., Keller J.M., Mayo M.L. et al. Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study. Endocrine 2018;59(3):573–84. DOI:10.1007/s12020-017-1509-9; Patel K.N., Angell T.E., Babiarz J. et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg 2018;153(9):817–24. DOI:10.1001/jamasurg.2018.1153; Титов С.Е., Лукьянов С.А., Козорезова Е.С. и др. Валидация дооперационной диагностики злокачественных опухолей щитовидной железы с помощью молекулярного классификатора. Вопросы онкологии 2022;68(6):741–51. DOI:10.37469/0507-3758-2022-68-6-741-751; Xing M., Liu R., Liu X. et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32(25):2718–26. DOI:10.1200/JCO.2014.55.5094; Xing M. Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Med 2016;14:12. DOI:10.1186/s12916-016-0559-9; Song Y.S., Park Y.J. Genomic characterization of differentiated thyroid carcinoma. Endocrinol Metab (Seoul) 2019;34(1):1–10. DOI:10.3803/EnM.2019.34.1.1; De Martino M., Esposito F., Capone M. et al. Noncoding RNAs in thyroid-follicular-cell-derived carcinomas. Cancers (Basel) 2022;14(13):3079. DOI:10.3390/cancers14133079; Macfarlane L.A., Murphy P.R. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010;11(7):537–61. DOI:10.2174/138920210793175895; Santiago K., Chen Wongworawat Y., Khan S. Differential microRNA-signatures in thyroid cancer subtypes. J Oncol 2020;2020:2052396. DOI:10.1155/2020/2052396; Wojtas B., Ferraz C., Stokowy T. et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol 2014;388(1–2):1–9. DOI:10.1016/j.mce.2014.02.011; Stokowy T., Wojtaś B., Fujarewicz K. et al. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. Horm Metab Res 2014;46(3):171–80. DOI:10.1055/s-0033-1363264; Weber F., Teresi R.E., Broelsch C.E. et al. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91(9):3584–91. DOI:10.1210/jc.2006-0693; Dom G., Frank S., Floor S. et al. Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution. Oncotarget 2017;9(12):10343–59. DOI:10.18632/oncotarget.23130; Titov S., Demenkov P.S., Lukyanov S.A. et al. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier. J Clin Pathol 2020;73(11):722–7. DOI:10.1136/jclinpath-2020-206445; Titov S.E., Kozorezova E.S., Demenkov P.S. et al. Preoperative typing of thyroid and parathyroid tumors with a combined molecular classifier. Cancers 2021;13(2):237. DOI:10.3390/cancers13020237; Andrews S. FastQC: a quality control tool for high throughput sequence data. Available at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/; Titov S.E., Ivanov M.K., Karpinskaya E.V. et al. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer 2016;16:201. DOI:10.1186/s12885-016-2240-2; Chen C., Ridzon D.A., Broomer A.J. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33(20):e179. DOI:10.1093/nar/gni178; Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001;25(4):402–8. DOI:10.1006/meth.2001.1262; Mercaldo N.D., Lau K.F., Zhou X.H. Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med 2007;26(20):2170–83. DOI:10.1002/sim.2677; Pérez-Ortiz M., Torres-Jiménez M., Gutiérrez P.A. et al. Fisher score-based feature selection for ordinal classification: a social survey on subjective well-being. In: Hybrid Artificial Intelligent Systems. Ed. by F. Martínez-Álvarez, A. Troncoso, H. Quintián, E. Corchado. HAIS 2016. Lecture Notes in Computer Science. Vol. 9648. Springer, Cham. DOI:10.1007/978-3-319-32034-2_50; Kononenko I., Šimec E., Robnik-Sikonja M. Overcoming the myopia of inductive learning algorithms with RELIEFF. Applied Intelligence 1997;7(1):39–55. DOI:10.1023/A:1008280620621; Li J., Cheng K., Wang S. et al. Feature selection. ACM Computing Surveys 2017;50(6):1–45. DOI:10.1145/3136625; Bylesjö M., Rantalainen M., Cloarec O. et al. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometrics 2006;20(8–10):341–51. DOI:10.1002/cem.1006; Thevenot E., Roux A., Xu Y. et al. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J Proteome Res 2015;14(8):3322–35. DOI:10.1021/acs.jproteome.5b00354; Tenenhaus M. La raegression PLS. Paris, Editions Technip, 1998.; Ricco R. TANAGRA: a free software for research and academic purposes. Proceedings of EGC’2005, RNTI-E-3. (In French). Available at: https://www.researchgate.net/publication/220786300_TANAGRA_un_logiciel_gratuit_pour_l'enseignement_et_la_recherche.; Quinlan J.R. C4.5: programs for machine learning. San Francisco: Morgan Kaufmann Publishers Inc; 1993.; Зиновьев А.Ю. Визуализация многомерных данных. Красноярск: Издательство КГТУ, 2000.; McHenry C.R., Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist 2011;16(5):585–93. DOI:10.1634/theoncologist.2010-0405; Valderrabano P., Leon M.E., Centeno B.A. et al. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol 2016;174(5):621–9. DOI:10.1530/EJE-15-1163; Rosai J., Kuhn E., Carcangiu M.L. Pitfalls in thyroid tumour pathology. Histopathology 2006;49:107–20. DOI:10.1111/j.1365-2559.2006.02451.x; Franc B., de la Salmonière P., Lange F. et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 2003;34(11):1092–100. DOI:10.1016/s0046-8177(03)00403-9; Cipriani N.A., Nagar S., Kaplan S.P. et al. Follicular thyroid carcinoma: how have histologic diagnoses changed in the last halfcentury and what are the prognostic implications? Thyroid 2015;25(11):1209–16. DOI:10.1089/thy.2015.0297; https://ogsh.abvpress.ru/jour/article/view/910

الاتاحة: https://ogsh.abvpress.ru/jour/article/view/910
https://doi.org/10.17650/2222-1468-2023-13-3-10-23

المؤلفون: D. O. Kuzmin, V. A. Manukovsky, S. F. Bagnenko, O. N. Reznik, A. N. Ananiev, O. A. Vorobyeva, S. L. Vorobyev, D. V. Gogolev, V. S. Daineko, A. A. Kutenkov, N. A. Chichagova, I. V. Uliankina, Д. О. Кузьмин, В. А. Мануковский, С. Ф. Багненко, О. Н. Резник, А. Н. Ананьев, О. А. Воробьёва, С. Л. Воробьёв, Д. В. Гоголев, В. С. Дайнеко, А. А. Кутенков, Н. А. Чичагова, И. В. Ульянкина

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 24, № 4 (2022); 124-134 ; Вестник трансплантологии и искусственных органов; Том 24, № 4 (2022); 124-134 ; 2412-6160 ; 1995-1191

مصطلحات موضوعية: поликлональные антитела, ischemia-reperfusion injury, polyclonal antibodies, ишемия-реперфузия

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1544/1395; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1160; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1161; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1162; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1163; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1164; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1165; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1166; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1167; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1168; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1169; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1170; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1171; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1172; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1173; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1174; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1175; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1232; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1233; https://journal.transpl.ru/vtio/article/downloadSuppFile/1544/1234; McFarlane PA. Should patients remain on intensive hemodialysis rather than choosing to receive a kidney transplant? Seminars in Dialysis. 2010; 23: 516–519. doi:10.1111/j.1525-139X.2010.00740.x. PMID: 21039877.; Bahadur MM, Binnani P, Gupta R, Pattewar S. Marginal donor kidney in a marginal recipient: Five year follow-up. Indian J Nephrol. 2010; 20 (2): 100–102. doi:10.4103/0971-4065.65306. PMID: 20835327.; Barba J, Zudaire J, Robles JE, Rosell D, Berian JM, Pascual I. Complications of kidney transplantation with grafts from expanded criteria donors. World J Urol. 2013; 31: 893–899. doi:10.1007/s00345-012-0831-3. PMID: 22290479.; Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997; 63: 968–974. doi:10.1097/00007890-199704150-00011. PMID: 9112349.; Perico N, Gaspari F, Remuzzi G. Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. American Journal of Transplantation. 2005; 5: 1175–1176. doi:10.1111/j.1600-6143.2005.00939.x. PMID: 15888019.; De Vries DK, Lindeman JHN, Ringers J, Reinders MEJ, Rabelink TJ, Schaapherder AFM. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. American Journal of Transplantation. 2011; 11 (5): 1064–1070. doi:10.1111/j.1600-6143.2011.03466.x. PMID: 21449948.; Yarlagadda SG, Coca SG, Formica Jr RN, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2009; 24 (3): 1039–1047. doi:10.1093/ndt/gfn667. PMID: 19103734.; Hashemi P et al. NETosis in ischemic/reperfusion injuries: An organ-based review. Life Sci. 2022; 290: 120158. doi:10.1016/j.lfs.2021.120158. PMID: 34822798.; Cahilog Z et al. The Role of Neutrophil NETosis in Organ Injury: Novel Inflammatory Cell Death Mechanisms. Inflammation. 2020; 43 (6): 2021–2032. doi:10.1007/s10753-020-01294-x. PMID: 32830308.; Nakamura K, Kageyama S, Kupiec-Weglinski JW. Innate immunity in ischemia-reperfusion injury and graft rejection. Curr Opin Organ Transplant. 2019; 24 (6): 687–693. doi:10.1097/MOT.0000000000000709. PMID: 31592839.; Иванов КП, Левкович ЮИ. Изменение микроциркуляции при лейкоцитозе. Физиол журн. 1992; 76: 321–326.; Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils – a key component of ischemia-reperfusion injury. Shock. 2013; 40 (6): 463–70. doi:10.1097/SHK.0000000000000044. PMID: 24088997.; Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiological reviews. 2019: 99 (2): 1223–1248. doi:10.1152/physrev.00012.2018.; Carbone F, Bonaventura A, Montecucco F. NeutrophilRelated Oxidants Drive Heart and Brain Remodeling After Ischemia/Reperfusion Injury. Front Physiol. 2020; 10: 1587. doi:10.3389/fphys.2019.01587. PMID: 32116732.; Tejchman K et al. The Role of Endothelins, IL-18, and NGAL in Kidney Hypothermic Machine Perfusion. Biomedicines. 2021; 9 (4): 417. doi:10.3390/biomedicines9040417. PMID: 33924469.; Qi H, Yang S, Zhang L. Neutrophil Extracellular Traps and Endothelial Dysfunction in Atherosclerosis and Thrombosis. Front Immunol. 2017; 8: 928. doi:10.3389/fimmu.2017.00928. PMID: 28824648.; Mittal M et al. Neutrophil Activation of Endothelial CellExpressed TRPM2 Mediates Transendothelial Neutrophil Migration and Vascular Injury. Circ Res. 2017; 121 (9): 1081–1091. doi:10.1161/circresaha.117.311747. PMID: 28790198.; Urisono Y et al. Von Willebrand Factor Aggravates Hepatic Ischemia-Reperfusion Injury by Promoting Neutrophil Recruitment in Mice. Thromb Haemost. 2018; 118 (4): 700–708. doi:10.1055/s-0038-1636529. PMID: 29618155.; Fernández AR, Sánchez-Tarjuelo R, Cravedi P, Ochando J, López-Hoyos M. Review: Ischemia Reperfusion Injury-A Translational Perspective in Organ Transplantation. Int J Mol Sci. 2020; 21 (22): 8549. doi:10.3390/ijms21228549. PMID: 33202744.; Trzpis M et al. Expression of EpCAM is up-regulated during regeneration of renal epithelia. J Pathol. 2008; 216 (2): 201–208. doi:10.1002/path.2396. PMID: 18702175.; Akhtar AM et al. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One. 2010; 5 (9): 34–35. doi:10.1371/journal.pone.0012800. PMID: 20877722.; Hanif Z et al. Role of biobanks in transplantation. Annals of medicine and surgery. 2018; 28: 30–33. doi:10.1016/j.amsu.2018.02.007.; https://journal.transpl.ru/vtio/article/view/1544

الاتاحة: https://journal.transpl.ru/vtio/article/view/1544
https://doi.org/10.15825/1995-1191-2022-4-124-134

المؤلفون: A. A. Musaelyan, S. V. Lapin, V. D. Nazarov, E. S. Kozorezova, S. L. Vorobyev, S. V. Orlov, А. А. Мусаелян, С. В. Лапин, В. Д. Назаров, Е. С. Козорезова, С. Л. Воробьев, С. В. Орлов

المصدر: Head and Neck Tumors (HNT); Том 12, № 2 (2022); 71-78 ; Опухоли головы и шеи; Том 12, № 2 (2022); 71-78 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-2

مصطلحات موضوعية: PAX8 / PPARG, molecular genetic diagnostics, fine needle aspiration biopsy, Bethesda IV, BRAF, TERT, RAS, RET / PTC, молекулярно-генетическая диагностика, тонкоигольная аспирационная биопсия

وصف الملف: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/779/533; Valderrabano P., McIver B. Evaluation and management of indeterminate thyroid nodules: the revolution of risk stratification beyond cytological diagnosis. Cancer Control 2017;24(5):1073274817729231-1073274817729231. DOI:10.1177/1073274817729231.; Partyka K.L., Trevino K., Randolph M.L. et al. Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine-needle aspiration. Diagn Cytopathol 2019 2019;47(9):853-62. DOI:10.1002/dc.24250.; Cibas E.S., Ali S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopatho-logy. Thyroid 2017;17(11):1341-6. DOI:10.1089/thy.2017.0500.; Steward D.L., Carty S.E., Sippel R.S. et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol 2019;5(2):204-12. DOI:10.1001/jamaoncol.2018.4616.; Ravella L., Lopez J., Descotes F. et al. Cytological features and nuclear scores: diagnostic tools in preoperative fine-needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations? Cytopathology 2021;32(1):37-44. DOI:10.1111/cyt.12904.; WHO classification of tumours of endocrine organs. Ed. by G. Kloppel, A. Couvelard, R.H. Hruban et al. Lyon, Fr World Heal Organ, 2017.; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133. DOI:10.1089/thy.2015.0020.; Bardet S., Goardon N., Lequesne J. et al. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study. Endocrine 2021;71(2):407-17. DOI:10.1007/s12020-020-02411-4.; Nikiforov Y.E., Buddinger P.W., Thompson L.D. Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practicing thyroid pathology. 3rd edn. 2020.; Penna G.C., Vaisman F., Vaisman M. et al. Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes. Cytogenet Genome Res 2016; 150(3-4):194-207. DOI:10.1159/000456576.; Jarry A., Masson D., Cassagnau E. et al. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 2004;18(5):349-52. DOI:10.1016/j.mcp.2004.05.004.; Liu T., Brown T.C., Juhlin C.C. et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014;21(3): 427-34. DOI:10.1530/ERC-14-0016.; Бельцевич Д.Г., Мудунов А.М., Ванушко В.Э. и др. Дифференцированный рак щитовидной железы. Современная онкология 2020;22(4):30-44. DOI:10.26442/18151434.2020.4.200507. =; Trimboli P., Treglia G., Condorelli E. et al. BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and metaanalysis. Clin Endocrinol (Oxf) 2016; 84(3):315-20. DOI:10.1111/cen.12806.; Pongsapich W., Chongkolwatana C., Poungvarin N. et al. BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma. Onco Targets Ther 2019;12:1465-73. DOI:10.2147/OTT.S190001.; Vuong H.G., Duong U.N.P., Altibi A.M.A. et al. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 2017;6(3):R8-17. DOI:10.1530/EC-17-0010.; Prete A., Borges de Souza P., Censi S. et al. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol 2020;11:102. DOI:10.3389/fendo.2020.00102.; Decaussin-Petrucci M., Descotes F., Depaepe L. et al. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology 2017;28(6):482-7. DOI:10.1111/cyt.12493.; Качко В.А., Ванушко В.Э., Платонова Н.М. и др. Возможности использования свободно циркулирующей ДНК плазмы крови в дооперационной диагностике при новообразованиях щитовидной железы. Проблемы эндокринологии 2019;65(6):400-7. DOI:10.14341/probl11311).; Nikiforov Y.E., Ohori N.P., Hodak S.P., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96(11):3390-7. DOI:10.1210/jc.2011-1469.; https://ogsh.abvpress.ru/jour/article/view/779

الاتاحة: https://ogsh.abvpress.ru/jour/article/view/779
https://doi.org/10.17650/2222-1468-2022-12-2-71-78

المؤلفون: V. Yu. Startsev, A. E. Balashov, A. S. Merzlyakov, S. L. Vorobiov, E. S. Kozorezova, В. Ю. Старцев, А. Е. Балашов, А. С. Мерзляков, С. Л. Воробьев, Е. С. Козорезова

المصدر: Cancer Urology; Том 17, № 3 (2021); 130-139 ; Онкоурология; Том 17, № 3 (2021); 130-139 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: циркулирующая опухолевая ДНК, recurrent bladder cancer, biomarker, mutation, fluid biopsy, circulating tumor DNA, рецидив рака мочевого пузыря, биомаркер, мутация, жидкостная биопсия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1521/1306; Witjes J.A. Follow-up in non-muscle invasive bladder cancer: facts and future. World J Urol 2020. DOI:10.1007/s00345-020-03569-2.; Cheng L., Lopez-Beltran A., MacLennan G.T. et al. Neoplasms of the urinary bladder. In: Urologic Surgical Pathology. Eds.: D.G. Bostwick, L. Cheng. Philadelphia, PA, USA: Elsevier/Mosby, 2008. Pp. 259-352.; Grossman H.B., Soloway M., Messing E. et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295(3):299—305. DOI:10.1001/jama.295.3.299.; Black P.C., Brown G.A., Dinney C.P. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006;24(35):5528—35. DOI:10.1200/JC0.2006.08.0895.; Bakkar A.A., Wallerand H., Radvanyi F. et al. FGFR3 and TP53 gene mutations define two distinct pathway sin urothelial cell carcinoma of the bladder. Cancer Res 2003;63(23):8108—12.; Lindgren D., Liedberg F., Andersson A. et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25(18):2685—96. DOI:10.1038/sj.onc.1209249.; Карелин М.И., Пожарисский К.М., Тен В. и др. Роль антигена Къ67, мутированного гена-супрессора p53 и онкобелка HER2/neu в определении прогноза клинического течения рака мочевого пузыря. Вопросы онкологии 2006;52(6):643—8.; Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nature Rev Cancer 2005;5(9):713—25. DOI:10.1038/nrc1697.; Lopez-Beltran A., Cheng L.C., Mazzucchelli R. et al. Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res 2008;28(5B):2893—900.; Lacy S., Lopez-Beltran A., Mac Lennan G.T. et al. Molecular pathogenesis of urothelial carcinoma: the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer. Anal Quan Cytol Histol 2009;31(1):5—16.; Wang L., Feng С., Ding G. et al. Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumour Biol 2014;35(4):2989—95. DOI:10.1007/s13277-013-1384-9.; Davidson D.D., Cheng L. “Field cancerization” in the urothelium of the bladder. Anal Quant Cytol Histol 2006;28(6):337—8.; Denzinger S., Mohren K., Knuechel R. et al. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization and p53 analyses. Hum Pathol 2006;37(2):143—51. DOI:10.1016/j.humpath.2005.10.014.; Dahse R., Gartner D., Werner W. et al. p53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences. Oncol Rep 2003;10(6):2033—7.; Jones T.D., Wang M., Eble J.N. et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11(18):6512—9. DOI:10.1158/1078-0432.CCR-05-0891.; Armstrong A.B., Wang M., Eble J.N. et al. TP53 mutation alanalysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol 2009;22(1):113—8. DOI:10.1038/modpathol.2008.176.; Ben-Porath I., Thomson M.W., Carey VJ. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40(5):499—507. DOI:10.1038/ng.127.; Atlasi Y., Mowla S.J., Ziaee S.A., Bahrami A.R. OCT4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007;120(7):1598—602. DOI:10.1002/ijc.22508.; She J.J., Zhang P.G., Wang Z.M. et al. Identification of side population cells from bladder cancer cells by Dye Cycle Violet staining. Cancer Biol Ther 2008;7(10):1663—8. DOI:10.4161/cbt.7.10.6637.; Barth I., Schneider U., Grimm T. et al. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Archiv 2018;472(5):749—58. DOI:10.1007/s00428-018-2354-9.; Babjuk M., Burger M., Capoun O. et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in situ). Eur Urol 2021;S0302— 2838(21)01978—3. DOI:10.1016/j.eururo.2021.08.010.; Pan C.X., Zhu W., Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol 2006;2(6):723—31. DOI:10.2217/14796694.2.6.723.; Cheng L., Zhang S., Davidson D.D. et al. Implications of cancer stem cells for cancer therapy. In: Cancer Drug Discovery and Development: Stem Cells and Cancer. Eds.: R.G. Bagley, B.A. Teicher. NY, USA: Humana Press/Springer, 2009.; Jebar A.H., Hurst C.D., Tomlinson D.C. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24(33):5218—25. DOI:10.1038/sj.onc.1208705.; Wolff E.M., Liang G., Jones P.A. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2(10):502—10. DOI:10.1038/ncpuro0318.; Worst T.S., Weis C.A., Stohr R. et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decisionmaking. Sci Rep 2018;8(1):14383. DOI:10.1038/s41598-018-32569-x.; Van Rhijn B.W., Montironi R., Zwarthoff E.C. et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198(2):245—51. DOI:10.1002/path.1202.; Van Rhijn B.W., van der Kwast T.H., Vis A.N. et al. FGFR3 and P53 chararacterize alternative genetic path ways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64(6):1911—4. DOI:10.1158/0008-5472.can-03-2421.; Pierrot B.I., Brams A., D.C. Dunois-Larde et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006;27(4):740—7. DOI:10.1093/carcin/bgi290.; Hernandez S., Lopez-Knowles E., Lloreta J. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24(22):3664—71. DOI:10.1200/JCO.2005.05.1771.; Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25(6):581 —93. DOI:10.1007/s00345-007-0213-4.; Barbisan F., Santinelli A., Mazzucchelli R. et al. Strong immuno histochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20 and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008;112.(3):636—44. DOI:10.1002/cncr.23212.; Lott S., Wang M., Zhang S. et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol 2009;22(5):627—32. DOI:10.1038/modpathol.2009.28.; Shariat S.F., Ashfaq R., Sagalowsky A.I., Lotan Y. Predictive value of cell cycle biomarkers in non-muscle invasive bladder transitional cell carcinoma. J Urol 2007;177(2):481 —7. DOI:10.1016/j.juro.2006.09.038.; Dyrskjot L., Thykjaer T., Kruhoffer M. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33(1):90—6. DOI:10.1038/ng1061.; Ito M., Nishiyama H., Kawanishi H. et al. P21-activated kinase 1, a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol 2007;178(3 Pt 1):1073—9. DOI:10.1016/j.juro.2007.05.012.; Choi Y.D., Cho N.H., Ahn H.S. et al. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J Urol 2007;177(3):1174—8. DOI:10.1016/j.juro.2006.10.031.; Margulis V., Shariat S.F., Ashfaq R. et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12(24):7369—73. DOI:10.1158/1078-0432.CCR-06-1472.; Helpap B., Schmitz-Drager B.J., Hamilton P.W. et al. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 2003;442(4):309—16. DOI:10.1007/s00428-002-0748-0.; Van Rhijn B.W, Lurkin I., Chopin D.K. et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003;9(1):257—63.; Lyu Q., Lin A., Cao M. et al. Alterations in TP53 are a potential biomarker of bladder cancer patients who benefit from immune checkpoint inhibition. Cancer Control 2020;27(1): 1073274820976665. DOI:10.1177/1073274820976665.; Chatterjee S.J., Datar R., Youssefzadeh D. et al. Combined effects of p53, p21 and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22(6):1007—13. DOI:10.1200/JCO.2004.05.174.; Calvete J., Larrinaga G., Errarte P. et al. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum Pathol 2019;91:61-8. DOI:10.1016/j.humpath.2019.07.002.; Karam J.A., Lotan Y., Karakiewicz P.I. et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8(2):128-36. DOI:10.1016/S1470-2045(07)70002-5.; Senol S., Yildirim A., Ceyran B. et al. Prognostic significance of survivin, p-catenin and p53 expression in urothelial carcinoma. Bosn J Basic Med Sci 2015;15(4):7—14. DOI:10.17305/bjbms.2015.556.; Li Q., Wang H., Peng H. et al. MicroRNAs: key players in bladder cancer. Mol Diagn Ther 2019;23(5):579—601. DOI:10.1007/s40291-019-00410-4.; Stoehr R., Zietz S., Burger M. et al. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005;47(1):58—63. DOI:10.1016/j.eururo.2004.07.012.; Lopez-Beltran A., Alvarez-Kindelan J., Luque R.J. et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 2008;215(3):263—72. DOI:10.1002/path.2353.; Edwards J., Duncan P., Going J.J. et al. Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer 2001;85(12):1894—9. DOI:10.1054/bjoc.2001.2159.; Fornari D., Steven K., Hansen A.B. et al. Transitional cell bladder tumor: predicting recurrence and progression by analysis of microsatellite loss of heterozygosity in urine sediment and tumor tissue. Cancer Genet Cytogenet 2006;167(1):15—9. DOI:10.1016/j.cancergencyto.2005.10.015.; Feng Y., Jiang Y., Wen T. et al. Identifying potential prognostic markers for muscle-invasive bladder urothelial carcinoma by weighted gene co-expression network analysis. Pathol Oncol Res 2019;26(2):1063—72. DOI:10.1007/s12253-019-00657-6.; Santoni G., Morelli M., Amantini C., Battelli N. Urinary markers in bladder cancer: an update. Front Oncol 2018;8:362. DOI:10.3389/fonc.2018.00362.; Yamada Y., Kato C., Arai T. et al. Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target. Mol Oncol 2019;13(9):1898—912. DOI:10.1002/1878-0261.12532.; Kim T.J., Moon H.W., Kang S. et al. UroVysion FISH could be effective and useful method to confirm the identity of cultured circulating tumor cells from bladder Cancer Patients. J Cancer 2019;10(14):3259—66. DOI:10.7150/jca.30079.; Gofrit O.N., Zorn K.C., Silvestre J. et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26(3):246—9. DOI:10.1016/j.urolonc.2007.02.011.; Nguyen C.T., Litt D.B., Dolar S.E. et al. Prognostic significance of non diagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology 2009;73(2):347—50. DOI:10.1016/j.urology.2008.09.042.; Zhao H., Grossman H.B., Delclos G.L. et al. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiate onto recurrence. Cancer 2005;104(1):30—5. DOI:10.1002/cncr.21136.; Dyrskjot L., Zieger K., Real F.X. et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13(12):3545—51. DOI:10.1158/1078-0432.CCR-06-2940.; Marques J.F., Reis J.P., Fernandes G. et al. Circulating tumor DNA: a step into the future of cancer management. Acta Cytol 2019;63(6):456—465. DOI:10.1159/000492917.; Lee J.S., Rhee T.M., Pietrasz D. et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci Rep 2019;9(1):16971. DOI:10.1038/s41598-019-53271-6.; Christensen E., Birkenkamp-Demtroder K., Sethi H. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37(18):1547—57. DOI:10.1200/JCO.18.02052.; Jones R.P., Pugh S.A., Graham J. et al. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. Eur J Cancer 2021;144:368-81. DOI:10.1016/j.ejca.2020.11.025.; Birkenkamp-Demtroder K., Christensen E., Nordentoft I. et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol 2018;73(4):535—40. DOI:10.1016/j.eururo.2017.09.011.; Powles T., Assaf Z.J., Davarpanah N. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595(7867):432—7. DOI:10.1038/s41586-021-03642-9.; Ding W., Tong S., Gou Y. et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 2015;33(12):1951—7. DOI:10.1007/s00345-015-1557-9.; Moustakas G., Kampantais S., Nikolaidou A. et al. HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy. J Int Med Res 2020;48(1):300060519895847. DOI:10.1177/0300060519895847.; Kiselyov A., Bunimovich-Mendrazhitsky S., Startsev V. Key signaling pathways in the muscle-invasive bladder carcinoma: clinical markers for disease modeling and optimized treatment. Int J Cancer 2016;138(11):2562—9. DOI:10.1002/ijc.29918.; Wolfs J.R.E., Hermans T.J.N., Koldewijn E.L., van de Kerkhof D. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: a review. Urol Oncol 2021;39(3):161 —70. DOI:10.1016/j.urolonc.2020.11.014.; https://oncourology.abvpress.ru/oncur/article/view/1521

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1521
https://doi.org/10.17650/1726-9776-2021-17-3-130-139

المؤلفون: V. V. Petrova, S. L. Vorob’ev, S. L. Nepomnyashchaya, G. A. Smirnov, M. N. Argelas, V. V. Davletshina, В. В. Петрова, С. Л. Воробьев, С. Л. Непомнящая, Г. А. Смирнов, М. Н. Аржелас, В. В. Давлетшина

المصدر: Wounds and wound infections. The prof. B.M. Kostyuchenok journal; Том 5, № 2 (2018); 90-99 ; Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка; Том 5, № 2 (2018); 90-99 ; 2500-0594 ; 2408-9613 ; undefined

مصطلحات موضوعية: коллагеновые биопластические материалы, necrotic pyogenic infection, surgical treatment, local treatment, wound healing, collagen bioplastic materials, некротическая пиогенная инфекция, хирургическое лечение, местное лечение, заживление ран

وصف الملف: application/pdf

Relation: https://www.riri.su/jour/article/view/148/151; Нестеренко В. Г., Кубанова А. А., Сафоян А. А., Суслов А. П., Забненкова О. В., Нестеренко С. В. Нативный нерекон-струированный коллаген «Коллост» – физиологическая матрица для коррекции дефектов кожи. Санкт-Петербургский институт красоты, ГУ НИИЭМ им. Н.Ф. Гамалеи РАМН, Москва. Тезисы 2 Форума Медицины и Красоты НАДК, 2009.; Rieger U.M., Gugger C.Y., Farhadi J. et al. Prognostic factors in necrotizing fasciitis and myositis: analysis of 16 consecutive cases at a single institution in Switzerland. Ann. Plast. Surg. 2007; 58 (5): 523–530.; Османов Э. Г., Анчиков Г. Ю. Современные принципы лечения гнойно-некротических заболеваний мягких тканей с большой площадью поражения. Медицинские науки. 2006; 1 (13): 37-39.; Ahrenholz D. H., Ripple J. M., Irwin R. S. et al. Necrotizing fasciitis and other infections. Intensive Care Medicine. 2 ed. Boston, Little, Brown, 1991. 1334 p.; Robson MC. Wound infection: a failure of wound healing caused by an imbalance of bacteria. Surg. Clin. North. Am. 1997; 77: 637-50.; Гринев М. В., Гринев К. М. Некротизирующий фасциит. СПб: Гиппократ, 2008. 120 с.; Гринев М.В., Гринев К.М. Некротизирующий фасциит в структуре хирургических инфекций мягких тканей. Амбулаторная хирургия. 2005; 3: 6–8.; Абаев Ю. К. Биология заживления острой и хронической раны. Медицинские новости. 2003; 6: 3-10.; Shaikh N., Khawaiter J., Al-Thani H. Necrotizing Fasciitis: A Surgical and Medical Emergency. Surgical Science. 2012; 3: 518–525.; Yuag-Meng L., Chih-Yu C., Mao-Wang H. et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J. Microbiol. Immunol. Infect. 2005; 38: 430–435.; Кузнецов Н. А., Никитин В. Г. Щадящие хирургические вмешательства и интерактивные повязки в лечении инфицированных ран. Consilium medicum. Хирургия. 2006; 8 (2).; Корейба К. А., Газиев А. Р. Хирургические инфекционные поражения кожи и мягких тканей. Лечение длительно незаживающих ран. Казань: АртПечатьСервис; 2011.; Chaby G, Senet P, Veneau M et al. Dressings for acute and chronic wounds. A systematic review. Arch Dermatol. 2007; 143: 1297-1304.; Fagien S. Facial soft–tissue augmentation with injactable autologous and allogeneic human tissue collagen matrix (autologen and dermalogen). Plast. Reconstr Surg. 2000; 105 (1): 362–373.; https://www.riri.su/jour/article/view/148

الاتاحة: https://www.riri.su/jour/article/view/148
https://doi.org/10.25199/2408-9613-2018-5-2-90-99